Retail investors miss rally in Gland Pharma; stock up 118% over IPO price

At the time of its IPO, retail investors bid for only 24 per cent or 0.24 times of the shares set aside for them

Retail investors on Dalal Street have missed the rally in Gland Pharma as the stock of the drug firm hit a new high of Rs 3,266, up 7 per cent on the BSE, in intra-day trade on Wednesday. In the last two days, the scrip has surged 17 per cent after the company reported a healthy 34 per cent year-on-year (YoY) rise in its consolidated net profit to Rs 260.4 crore in the March 2021 quarter (Q4FY21) on robust sales.

The company’s revenue from operations grew 40 per cent YoY at Rs 887.70 crore from Rs 635.2 crore in the year-ago